Anzeige
Mehr »
Dienstag, 12.08.2025 - Börsentäglich über 12.000 News
Diese Aktie liegt in der Turbo-Zone - und könnte der Gold-Gewinner 2025/26 werden!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40LEL | ISIN: US00439U1043 | Ticker-Symbol: L8S
NASDAQ
12.08.25 | 22:00
3,170 US-Dollar
-1,86 % -0,060
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
GRACE THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
GRACE THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur GRACE THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
14:18Grace Therapeutics GAAP EPS of -$0.21 beats by $0.012
GRACE THERAPEUTICS Aktie jetzt für 0€ handeln
14:06Grace Therapeutics, Inc.: Grace Therapeutics Announces First Quarter 2026 Financial Results, Provides Business Update68Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for GTx-104 Seeking Approval of GTx-104 in the Treatment of Patients with aneurysmal Subarachnoid Hemorrhage (aSAH)...
► Artikel lesen
14:01Grace Therapeutics, Inc. - 8-K, Current Report1
13:31Grace Therapeutics, Inc. - 10-Q, Quarterly Report1
25.06.Grace Therapeutics, Inc.: Grace Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for GTx-104190Submission Seeks Approval of GTx-104 in the Treatment of Patients with aneurysmal Subarachnoid Hemorrhage (aSAH) Comprehensive Data Package Includes Positive Results from Phase 3 STRIVE-ON Safety...
► Artikel lesen
23.06.Grace Therapeutics GAAP EPS of -$0.791
23.06.Grace Therapeutics, Inc. - 8-K, Current Report1
23.06.Grace Therapeutics, Inc. - 10-K, Annual Report2
02.05.TD Cowen starts Grace Therapeutics stock with Buy, $12 target3
09.04.Grace Therapeutics aligns with FDA on GTx-104 NDA submission3
09.04.Grace Therapeutics einigt sich mit FDA über GTx-104 NDA-Einreichung3
09.04.Grace Therapeutics, Inc.: Grace Therapeutics Announces Alignment with the FDA Supporting the Planned NDA Submission for GTx-104473PRINCETON, N.J., April 09, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage...
► Artikel lesen
09.04.Grace Therapeutics, Inc. - 8-K, Current Report1
03.03.Grace Therapeutics, Inc. - 8-K, Current Report-
19.02.Grace Therapeutics, Inc. - 10-Q/A, Quarterly Report-
18.02.H.C. Wainwright reiterates buy on Grace Therapeutics stock4
13.02.Grace Therapeutics GAAP EPS of -$0.36 misses by $0.042
13.02.Grace Therapeutics, Inc.: Grace Therapeutics Announces Third Fiscal Quarter 2025 Financial Results, Provides Business Update229Announced Phase 3 STRIVE-ON Safety Trial Met Primary Endpoint and Provided Clinical Benefit Compared to Orally Administered Nimodipine; New Drug Application (NDA) Submission Anticipated First Half...
► Artikel lesen
13.02.Grace Therapeutics, Inc. - 10-Q, Quarterly Report-
10.02.Grace Therapeutics, Inc.: Grace Therapeutics Announces Results From Pivotal Phase 3 STRIVE-ON Safety Trial of GTx-104 in aSAH262Trial Met the Primary Endpoint and Provides Evidence of GTx-104 Clinical Benefit Compared to Orally Administered Nimodipine New Drug Application (NDA) Submission Expected in the First Half of 2025...
► Artikel lesen
Weiter >>
27 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1